PD-1 knockout T cell therapy - CELLBIOTECH

Drug Profile

PD-1 knockout T cell therapy - CELLBIOTECH

Latest Information Update: 30 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CELLBIOTECH
  • Class Antineoplastics; Gene therapies; T lymphocyte cell therapies
  • Mechanism of Action Gene transference; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 12 Aug 2016 Cell Biotech and Peking University plan a phase I trial for Prostate cancer (Hormone refractory) in China (Parenteral) (NCT02867345)
  • 11 Aug 2016 Preclinical trials in Solid tumours in South Korea (Parenteral) before August 2016
  • 11 Aug 2016 Cell Biotech and Peking University plan a phase I trial for Renal cell carcinoma (Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (Parenteral) (NCT02867332)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top